Zacks.com on MSN3d
Ionis' Q4 Earnings and Sales Beat Estimates, Tryngolza Launch in Focus
Ionis Pharmaceuticals IONS incurred a loss of 66 cents per share for fourth-quarter 2024, which was narrower than the Zacks ...
precisionmedicineonline3d
Intellia Therapeutics' In Vivo CRISPR Drug Could Offer One-Time Fix for ATTR Amyloidosis
A Phase III trial evaluating nex-z in transthyretin amyloidosis with cardiomyopathy is underway, with plans for another ...
Ionis Continues to Expand Its Cardiology and Neurology Portfolio, Supporting Narrow Moat
Ionis relies on upfront payments and licensing fees from partners, as well as Spinraza royalties, to drive revenue today, but its rapidly advancing portfolio should help diversify revenue. 2025 is ...
2 Hot Growth Stocks Poised for Gains of Up to 370%, According to Wall Street
While investing in biotech stocks can be risky due to clinical trial failures and regulatory hurdles, successful drug approvals can result in massive stock gains. Let’s look at two such growth stocks ...